This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Margaret Hudson; Clare Nash, RPh
Royal Hallamshire Hospital Sheffield, England

JAMA. 1996;276(14):1140.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Recent studies have shown encouraging antiretroviral and immunological benefit from the combination of lamivudine and zidovudine.^1-3 The cost of such combination therapy (with the possible addition of human immunodeficiency virus [HIV] protease inhibitors and nonnucleoside reverse transcriptase inhibitors) is considerable.

A little publicized fact is that trimethoprim increases the bioavailability of lamivudine by approximately 40%.⁴ It is not stated in any of these trials precisely how many patients were receiving trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia prophylaxis. Trials of combination therapy of trimethoprim and lamivudine may show that lower doses of lamivudine are effective with significant cost benefits. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?